Philippe Drouet, Biotheryx CEO
April 5, 2023 10:59 AM EDTUpdated 11:11 AM
Deals
R&D

In­cyte links arms with tiny Bio­th­eryx for pro­tein de­grad­er deal, tar­get­ing can­cer

Paul Schloesser

Associate Editor

In­cyte is jump­ing in on Bio­th­eryx’s plat­form, look­ing for po­ten­tial pro­tein de­graders for a new, undis­closed on­col­o­gy tar­get.

The deal,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times